TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer
BD Lehmann, VG Abramson, ME Sanders… - Clinical Cancer …, 2020 - AACR
Purpose: Preclinical data demonstrating androgen receptor (AR)–positive (AR+) triple-
negative breast cancer (TNBC) cells are sensitive to AR antagonists, and PI3K inhibition …
negative breast cancer (TNBC) cells are sensitive to AR antagonists, and PI3K inhibition …
Targeting the androgen receptor in triple-negative breast cancer: current perspectives
A Mina, R Yoder, P Sharma - OncoTargets and therapy, 2017 - Taylor & Francis
Triple-negative breast cancer (TNBC) is an aggressive subtype associated with frequent
recurrence and metastasis. Unlike hormone receptor-positive subtypes, treatment of TNBC …
recurrence and metastasis. Unlike hormone receptor-positive subtypes, treatment of TNBC …
Targeting the androgen receptor in triple-negative breast cancer
A Gucalp, TA Traina - Current problems in cancer, 2016 - Elsevier
Triple-negative breast cancer represents approximately 15%-20% of all newly diagnosed
breast cancers, but it accounts for a disproportionate number of breast cancer-related deaths …
breast cancers, but it accounts for a disproportionate number of breast cancer-related deaths …
Newly developed targeted therapies against the androgen receptor in triple-negative breast cancer: A review
Among different types of breast cancers (BC), triple-negative BC (TNBC) amounts to 15% to
20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme …
20% of breast malignancies. Three principal characteristics of TNBC cells are (i) extreme …
[HTML][HTML] Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
F Coussy, M Lavigne, L De Koning, R El Botty… - Theranostics, 2020 - ncbi.nlm.nih.gov
Luminal androgen receptor (LAR) breast cancer accounts for 10% of all triple-negative
breast cancers (TNBC). Anti-androgen therapy for this subtype is in development, but yields …
breast cancers (TNBC). Anti-androgen therapy for this subtype is in development, but yields …
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).
TA Traina, K Miller, DA Yardley, J O'Shaughnessy… - 2015 - ascopubs.org
1003 Background: The AR may be a therapeutic target for pts with androgen-driven TNBC.
ENZA, a potent AR inhibitor, is approved in men with metastatic castration-resistant prostate …
ENZA, a potent AR inhibitor, is approved in men with metastatic castration-resistant prostate …
[HTML][HTML] Role of the androgen receptor in triple-negative breast cancer
M Rampurwala, KB Wisinski… - Clinical advances in …, 2016 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is an aggressive disease with outcomes inferior to
those of other breast cancer subtypes. No targeted therapies are currently approved for …
those of other breast cancer subtypes. No targeted therapies are currently approved for …
[HTML][HTML] PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
BD Lehmann, JA Bauer, JM Schafer… - Breast Cancer …, 2014 - Springer
Introduction Triple negative breast cancer (TNBC) is a heterogeneous collection of
biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we …
biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we …
Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer
TA Traina, K Miller, DA Yardley, J Eakle… - Journal of clinical …, 2018 - ascopubs.org
Purpose Studies suggest that a subset of patients with triple-negative breast cancer (TNBC)
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor …
have tumors that express the androgen receptor (AR) and may benefit from an AR inhibitor …
[HTML][HTML] Ceritinib is a novel triple negative breast cancer therapeutic agent
S Dong, H Yousefi, IV Savage, SC Okpechi, MK Wright… - Molecular cancer, 2022 - Springer
Background Triple-negative breast cancers (TNBCs) are clinically aggressive subtypes of
breast cancer. TNBC is difficult to treat with targeted agents due to the lack of commonly …
breast cancer. TNBC is difficult to treat with targeted agents due to the lack of commonly …
相关搜索
- breast cancer androgen receptor
- breast cancer pi3k inhibitors
- breast cancer molecular insights
- pi3k inhibitors androgen receptor
- breast cancer enzalutamide enza
- breast cancer pik3ca mutations
- breast cancer standard therapy
- breast cancer combination of pi3k
- breast cancer enzalutamide for the treatment
- breast cancer targeted therapies